Network meta-analysis of heart failure prevention by antihypertensive drugs - Reply

Archives of Internal Medicine

Volumn 171, Issue 5, 2011, Pages 472-473

  Sciarretta, Sebastiano ^a   Tocci, Giuliano ^a   Palano, Francesca ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ANGIOGRAPHY; ANTIHYPERTENSIVE THERAPY; CLINICAL ASSESSMENT; CLINICAL STUDY; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; HEART FAILURE; HEMODYNAMICS; LETTER; MEDICAL RESEARCH; META ANALYSIS (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; SYSTEMATIC ERROR; HUMAN; HYPERTENSION; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; HEART FAILURE; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952609024     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.58     Document Type: Letter

References (7)

1. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk [published online November 8, 2010]. Arch Intern Med. 2011;171(5):384-394.
2. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009;30(6):679-688.
3. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
4. Kasanuki H, Hagiwara N, Hosoda S, et al; HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009;30(10):1203-1212.
5. Ogihara T, Nakao K, Fukui T, et al; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51(2):393-398. (Pubitemid 351159955)
6. Sawada T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009;30(20):2461-2469.
7. Mochizuki S, Dahlöf B, Shimizu M, et al; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431-1439. (Pubitemid 46635780)